X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2322) 2322
azacitidine - therapeutic use (1326) 1326
azacitidine - analogs & derivatives (1181) 1181
oncology (1129) 1129
male (1071) 1071
female (1057) 1057
azacitidine - pharmacology (920) 920
hematology (860) 860
dna methylation (843) 843
aged (805) 805
middle aged (782) 782
azacitidine (692) 692
cancer (684) 684
antimetabolites, antineoplastic - therapeutic use (642) 642
myelodysplastic syndromes - drug therapy (621) 621
decitabine (586) 586
animals (552) 552
adult (522) 522
methylation (522) 522
treatment outcome (507) 507
azacitidine - administration & dosage (458) 458
cell line, tumor (457) 457
dna methylation - drug effects (452) 452
myelodysplastic syndromes (442) 442
leukemia, myeloid, acute - drug therapy (429) 429
aged, 80 and over (410) 410
leukemia (387) 387
acute myeloid-leukemia (384) 384
myelodysplastic syndrome (357) 357
mice (332) 332
expression (323) 323
azacitidine - adverse effects (318) 318
gene expression (318) 318
antineoplastic combined chemotherapy protocols - therapeutic use (312) 312
prognosis (311) 311
epigenetics (299) 299
research (293) 293
antineoplastic agents - therapeutic use (277) 277
care and treatment (267) 267
chemotherapy (264) 264
5-aza-2'-deoxycytidine (250) 250
5-azacytidine (240) 240
analysis (239) 239
acute myeloid leukemia (236) 236
dna (225) 225
therapy (225) 225
hematology, oncology and palliative medicine (219) 219
antimetabolites, antineoplastic - pharmacology (216) 216
genetic aspects (214) 214
apoptosis (212) 212
dna modification methylases - antagonists & inhibitors (209) 209
transplantation (208) 208
stem cells (202) 202
deoxyribonucleic acid--dna (199) 199
cell biology (191) 191
genes (186) 186
myelodysplastic syndromes - genetics (181) 181
conventional care regimens (180) 180
epigenesis, genetic (180) 180
pharmacology & pharmacy (178) 178
medicine & public health (176) 176
promoter regions, genetic (174) 174
gene expression regulation, neoplastic - drug effects (172) 172
tumors (172) 172
antineoplastic agents (171) 171
survival (171) 171
myelodysplastic syndromes - mortality (167) 167
health aspects (166) 166
proteins (164) 164
enzyme inhibitors - pharmacology (163) 163
antimitotic agents (161) 161
remission induction (160) 160
research article (160) 160
leukemia, myeloid, acute - genetics (159) 159
retrospective studies (156) 156
mds (155) 155
cells (152) 152
myelodysplastic syndromes - therapy (149) 149
antimetabolites, antineoplastic - adverse effects (147) 147
leukemia, myeloid, acute - mortality (146) 146
aml (144) 144
medicine (143) 143
mutation (142) 142
gene-expression (141) 141
gene (139) 139
myelodysplastic syndromes - pathology (139) 139
survival analysis (139) 139
dose-response relationship, drug (138) 138
cell proliferation - drug effects (135) 135
epigenesis, genetic - drug effects (135) 135
drug therapy (133) 133
adolescent (132) 132
antimetabolites, antineoplastic - administration & dosage (132) 132
clinical trials as topic (132) 132
risk factors (132) 132
medicine, research & experimental (131) 131
enzyme inhibitors - therapeutic use (130) 130
apoptosis - drug effects (129) 129
hypomethylating agents (129) 129
differentiation (128) 128
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2605) 2605
Japanese (35) 35
Chinese (29) 29
Spanish (9) 9
German (8) 8
French (7) 7
Polish (4) 4
Italian (3) 3
Russian (3) 3
Czech (1) 1
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 12/2017, Volume 268, pp. 92 - 101
.... In addressing key issues of reducing toxic side effects and improving pharmacokinetic profiles of the therapeutic agents, we have developed a new formulation by co-packaging DAC and ATO... 
Bone marrow | Decitabine | Arsenic trioxide | Delivery | Nanoparticle | Myelodysplastic syndrome | APOPTOSIS | DNA METHYLATION | DRUG-DELIVERY | 5-AZACYTIDINE | COMBINATION | CANCER | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | RETINOIC ACID | PHARMACOLOGY & PHARMACY | POLYMER HYBRID NANOPARTICLES | ACUTE PROMYELOCYTIC LEUKEMIA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Nanoparticles - chemistry | Apoptosis - drug effects | Oxides - chemistry | Azacitidine - chemistry | Phosphatidylethanolamines - therapeutic use | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Polyethylene Glycols - therapeutic use | Alendronate - chemistry | Alendronate - therapeutic use | Tissue Distribution | Arsenicals - therapeutic use | Nanoparticles - therapeutic use | Bone and Bones - metabolism | Phosphatidylethanolamines - pharmacokinetics | Bone Marrow Cells - drug effects | Antineoplastic Agents - pharmacokinetics | Arsenicals - pharmacokinetics | Alendronate - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Oxides - administration & dosage | Azacitidine - administration & dosage | Oxides - therapeutic use | Cell Survival - drug effects | Arsenic Trioxide | Azacitidine - pharmacokinetics | Myelodysplastic Syndromes - metabolism | Cells, Cultured | Polyethylene Glycols - pharmacokinetics | Azacitidine - analogs & derivatives | Mice, Transgenic | Phosphatidylethanolamines - administration & dosage | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Oxides - pharmacokinetics | Arsenicals - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Arsenicals - chemistry | Nanoparticles - administration & dosage | Phosphatidylethanolamines - chemistry | Alendronate - administration & dosage | Azacitidine - therapeutic use | Medical research | Medical colleges | Medical examination | Arsenic | Analysis | Medicine, Experimental | Hematopoietic stem cells | Blood | Index Medicus | delivery | nanoparticle | decitabine | arsenic trioxide | bone marrow
Journal Article
Journal Article
Cancer, ISSN 1097-0142, 2019, Volume 125, Issue 18, pp. 3121 - 3130
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission still can have measurable residual disease (MRD) detected by... 
acute myeloid leukemia (AML) | clinical trials | complete remission | measurable residual disease (MRD) | Triazines - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Decitabine | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Transplantation, Homologous | Pyrrolidines - therapeutic use | Neoplasm, Residual | Molecular Diagnostic Techniques | Flow Cytometry | Aminopyridines - therapeutic use | Azacitidine | Cytogenetic Analysis | Leukemia, Myeloid, Acute - therapy | Triazoles - therapeutic use | Hydrazines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Hematopoietic Stem Cell Transplantation | In Situ Hybridization, Fluorescence | Nivolumab - therapeutic use | Enzyme Inhibitors - therapeutic use | Remission Induction | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Agents, Immunological - therapeutic use | Lenalidomide - therapeutic use | Protein Kinase Inhibitors - therapeutic use | para-Aminobenzoates - therapeutic use | Aniline Compounds - therapeutic use | Immunologic Factors - therapeutic use | AML | PROGNOSTIC IMPACT | GEMTUZUMAB OZOGAMICIN | HEMATOPOIETIC-CELL TRANSPLANTATION | RISK STRATIFICATION | IMPROVE OUTCOMES | RELAPSE | ONCOLOGY | FLOW-CYTOMETRY | DIRECTED THERAPY | Flow cytometry | Myeloid leukemia | Leukemia | Medical treatment | Health risks | Clinical trials | Transplantation | Patients | Hemopoiesis | Risk assessment | Cytogenetics | Remission | Acute myeloid leukemia
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 02/2011, Volume 18, Issue 5, pp. 638 - 666
For the last twenty years, significant progress in Molecular and Cellular Biology has resulted in a better characterization and understanding of the biology... 
AML | MTOR kinase inhibitors | Histone deacetylase inhibitors | Hypomethylating agents | Monoclonal antibodies | Farnesyl transferase inhibitors | Liposomal daunorubicin | Nucleoside analogs | ANTI-CD33 MONOCLONAL-ANTIBODY | HISTONE DEACETYLASE INHIBITOR | CHEMISTRY, MEDICINAL | liposomal daunorubicin | SUBEROYLANILIDE HYDROXAMIC ACID | BIOCHEMISTRY & MOLECULAR BIOLOGY | mTOR kinase inhibitors | ACUTE MYELOGENOUS LEUKEMIA | RISK MYELODYSPLASTIC SYNDROME | POPULATION PHARMACOKINETIC MODEL | FARNESYL TRANSFERASE INHIBITOR | hypomethylating agents | PHASE-II TRIAL | nucleoside analogs | REFRACTORY HEMATOLOGIC MALIGNANCIES | PHARMACOLOGY & PHARMACY | SULFONYLHYDRAZINE ALKYLATING AGENT | farnesyltransferase inhibitors | histone deacetylase inhibitors | monoclonal antibodies | Cytosine - analogs & derivatives | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Cytarabine - therapeutic use | Liposomes - administration & dosage | Humans | Decitabine | Cytarabine - analogs & derivatives | Dioxolanes - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Leukemia, Myeloid, Acute - drug therapy | Valproic Acid - therapeutic use | Cytosine - therapeutic use | Farnesyltranstransferase - antagonists & inhibitors | Daunorubicin - administration & dosage | Hydrazines - therapeutic use | Azacitidine - analogs & derivatives | Adenine Nucleotides - therapeutic use | Clofarabine | Piperazines - therapeutic use | Imatinib Mesylate | Arabinonucleosides - therapeutic use | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Benzamides | Azacitidine - therapeutic use | Drugs | Protein kinase C | Prognosis | RNA | Pharmacology | Drug development | Farnesyl-diphosphate farnesyltransferase | Chemotherapy | Reviews | DNA methylation | pyrimidines | Methylation | Acute myeloid leukemia | 5-aza-2'-deoxycytidine | Geriatrics
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 14, pp. 1591 - 1597
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2014, Volume 27, Issue 2, pp. 197 - 208
Agents targeting the JAK-STAT pathway have dominated the investigational therapeutic portfolio over the last five years resulting in the first and only approved agent for the treatment of patients with myelofibrosis (MF... 
Hematology, Oncology and Palliative Medicine | myelofibrosis | LDE225 | combination therapy | PRM-151 | ruxolitinib | decitabine | panobinostat | Panobinostat | Ruxolitinib | Myelofibrosis | Decitabine | Combination therapy | CHRONIC IDIOPATHIC MYELOFIBROSIS | INTERNATIONAL-WORKING-GROUP | BLAST PHASE | MYELOPROLIFERATIVE NEOPLASMS | ACUTE MYELOID-LEUKEMIA | BONE-MARROW FIBROSIS | PAN-DEACETYLASE INHIBITOR | JAK2 INHIBITOR | SERUM AMYLOID P | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Hematopoietic Stem Cells - pathology | Primary Myelofibrosis - pathology | Biphenyl Compounds - therapeutic use | Serum Amyloid P-Component - therapeutic use | Drug Therapy, Combination | Janus Kinase 2 - antagonists & inhibitors | Pyridines - therapeutic use | Hematopoietic Stem Cells - drug effects | Primary Myelofibrosis - drug therapy | Gene Expression | Janus Kinase 2 - genetics | Azacitidine - analogs & derivatives | Clinical Trials as Topic | Hematopoietic Stem Cells - metabolism | Antimetabolites, Antineoplastic - therapeutic use | Primary Myelofibrosis - genetics | Homeodomain Proteins - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Mutation | Azacitidine - therapeutic use | Analysis | Hematopoietic stem cells
Journal Article
Journal Article
Seminars in Oncology, ISSN 0093-7754, 10/2011, Volume 38, Issue 5, pp. 682 - 692
Journal Article
Cell Death and Disease, ISSN 2041-4889, 09/2013, Volume 4, Issue 9, pp. e798 - e798
Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of... 
Extrinsic apoptosis | DNA methylation | Histone deacetylase inhibitors | Intrinsic apoptosis | Multiple myeloma | HDAC INHIBITORS | multiple myeloma | intrinsic apoptosis | BH3 MIMETIC ABT-737 | ANTITUMOR ACTIVITIES | TRAIL RECEPTOR AGONIST | extrinsic apoptosis | CELL-DEATH | CELL BIOLOGY | MURINE MODEL | APOPTOSIS-INDUCING LIGAND | MOUSE MODEL | CHEMOTHERAPEUTIC-AGENT | RESISTANCE | histone deacetylase inhibitors | Apoptosis - drug effects | Humans | Recombinant Proteins | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Death Domain - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Multiple Myeloma - drug therapy | TNF-Related Apoptosis-Inducing Ligand - pharmacology | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Nitrophenols - therapeutic use | Indoles - pharmacology | Hydroxamic Acids - pharmacology | Mice, Inbred C57BL | Mice, Transgenic | Piperazines - therapeutic use | Multiple Myeloma - metabolism | Sulfonamides - pharmacology | Piperazines - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | TNF-Related Apoptosis-Inducing Ligand - therapeutic use | Azacitidine - pharmacology | Multiple Myeloma - pathology | Animals | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Mice | Azacitidine - therapeutic use | Drug Screening Assays, Antitumor | Original
Journal Article